Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism

Yan, Zhidong; Zhuansun, Yongxun; Chen, Rui; Li, Jianguo; Ran, Pixin

doi:10.1016/j.yexcr.2014.03.013

Cited by 79 publications

(67 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, an important finding was reported by Yan and colleagues [74]. Using a coculture system, they showed that MSCs are able to enhance the suppressive potential of Tregs by promoting an upregulation of PD-1 on these cells.…”

Section: Mechanisms Of Immunosuppressionmentioning

confidence: 96%

Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?

Haddad

Saldanha-Araújo

2014

BioMed Research International

147

123

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) are multipotent cells, which can give rise to several cell types including osteoblasts, adipocytes, and chondroblasts. These cells can be found in a variety of adult and fetal tissues, such as bone marrow, adipose tissue, cord blood, and placenta. In recent years, the biological properties of MSCs have attracted the attention of researchers worldwide due to their potential application for treating a series of clinical situations. Among these properties, special attention should be given to the immunoregulatory potential of those cells. MSCs are able to act on all cells of the immune system, which includes the capacity to inhibit the proliferation and function of T-cells. This feature renders them natural candidates to treat several diseases in which cellular immune response is exacerbated. In this review, we outline the main mechanisms by which MSCs immunosuppress T-cell response, focusing on cell-cell contact, secretion of soluble factors, and regulatory T-cell generation. The influence of surface markers in the immunosuppression process and features of MSCs isolated from different sources are also discussed. Finally, the influences of toll-like receptors and cytokines on the inflammatory microenvironment are highlighted regarding the activation of MSCs to exert their immunoregulatory function.

show abstract

Section: Mechanisms Of Immunosuppressionmentioning

confidence: 96%

Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?

Haddad

Saldanha-Araújo

2014

BioMed Research International

147

123

View full text Add to dashboard Cite

show abstract

“…Yan et al reported that MSC-exposed Treg cells are capable of more immunosuppressive than Tregs without coculturing with MSCs. And their results showed that programmed cell death 1 receptor/B7-H1 interactions and IL-10 might be responsible for the enhanced suppressive capability of MSC-exposed regulatory T cells [75]. However, depletion of regulatory T cells had no effect on the suppression of T cell proliferation by MSCs, and MSCs physically hinder T cells from the contact with antigen presenting cells (APCs) in a noncognate fashion [76].…”

Section: Mscs Inhibit T Cells Proliferation and Suppress Allogeneic Tmentioning

confidence: 99%

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Zhao¹,

Ren

Han

2016

Journal of Cellular Immunotherapy

249

200

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) represent a heterogenous population of adult,fibroblast-like multi-potent cells. MSCs have drawn much attention during the last decade in the field of regenerative medicine, mainly due to their capacity to differentiate into specific cell types, abundant production of soluble growth factors and cytokines, and hematopoiesis supporting properties. In addition, MSCs can migrate to the sites of inflammation and hold potent of immunomodulatory and anti-inflammatory effects through cell and cell interactions between MSCs and lymphocytes or production of soluble factors. Therefore, the application of MSCs in many disease situations is full of possibilities for future clinical treatment. Phase III clinical trials have been run using

show abstract

“…44,45 Other molecules released from MSCs (HLA-G5, PGE2, IL-10, NO, IDO, and HO-1) exert anti-inflammatory and immune-modulatory effects, such as inhibition of dendritic cell differentiation/ activation, inhibition of CD4+/CD8+ T cell proliferation/cytokine release, reprogramming of macrophages toward an M2 phenotype, 46 and stimulation of T regulatory cells. 47,48 On the basis of these preclinical data, MSCs have been evaluated in clinical trials in patients with AKI with promising results (suprarenal aortic infusion in patients of cardiac surgery and induction therapy in patients of oncology with kidney transplantation subjected to cisplatin chemotherapy). [48][49][50] Although no serious adverse effects have been reported in trials, 51 a note of caution rose from experimental studies, in which the possibility of MSC maldifferentiation, tumorigenesis, and overimmunodepression has been reported.…”

Section: What Aspects Of Repair Can Be Targeted Therapeutically?mentioning

confidence: 99%

Targeting Endogenous Repair Pathways after AKI

Humphreys

Cantaluppi

Portilla

et al. 2016

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

AKI remains a highly prevalent disease associated with poor short-and long-term outcomes and high costs. Although significant advances in our understanding of repair after AKI have been made over the last 5 years, this knowledge has not yet been translated into new AKI therapies. A consensus conference held by the Acute Dialysis Quality Initiative was convened in April of 2014 and reviewed new evidence on successful kidney repair to identify the most promising pathways that could be translated into new treatments. In this paper, we provide a summary of current knowledge regarding successful kidney repair and offer a framework for conceptualizing the therapeutic targeting that may facilitate this process. We outline gaps in knowledge and suggest a research agenda to more efficiently bring new discoveries regarding repair after AKI to the clinic.

show abstract

Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism

Cited by 79 publications

References 58 publications

Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?

Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Targeting Endogenous Repair Pathways after AKI

Contact Info

Product

Resources

About